Plain-English translation of NCT06206174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is the first trial of in humans with blood cancers. Researchers want to find the right dose of this medication and learn whether it is safe and whether it helps people with non-Hodgkin lymphoma, acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes. The study will also test whether the medication works better when combined with other treatments.
This medication is brand new and has never been tested in patients before. The trial exists to find a safe dose and to get an early sense of whether this treatment might help people with blood cancers who may have limited options.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth once each day. The study starts with small doses that are gradually increased to find the safest dose, and you will be closely monitored for side effects and how your cancer responds. You will have visits for blood tests, physical exams, and heart monitoring to make sure the medication is safe for you.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China